LUPITRA 0.120 mg/0.015 mg per 24 hours, Price in UAE

Overview

Welcome to Dwaey, specifically on LUPITRA 0.120 mg/0.015 mg per 24 hours, page.
This medicine contains an important and useful components, as it consists of
Etonogestrel/Ethinyl estradiolis available in the market in concentration

Name

Etonogestrel + Ethinylestradiol

Precaution

1 Thromboembolic Disorders and Other Vascular Problems 2 Toxic Shock Syndrome (TSS) 3 Liver Disease 4 High Blood Pressure 5 Vaginal Use 6 Gallbladder Disease 7 Carbohydrate and Lipid Metabolic Effects 8 Headache 9 Bleeding Irregularities and Amenorrhea 10 Inadvertent Urinary Bladder Insertion 11 CHC Use Before or During Early Pregnancy 12 Depression 13 Carcinoma of the Breasts and Cervix 14 Effect on Binding Globulins 15 Monitoring 16 Hereditary Angioedema 17 Chloasma Lactation: Small amounts of steroids are excreted in breast milk; estrogens may reduce quality/quantity of milk; may be prudent to use other forms of birth control until full weaning (AAP Committee states compatible w/ nursing)

Indication

Contraception

Contra indication

Documented hypersensitivity Arterial thromboembolic disease (stroke, MI), thrombophlebitis, DVT/PE, thrombogenic valvular disease Estrogen-dependent neoplasia (current or history of) Cerebrovascular disease, coronary artery disease Headaches with focal neurological symptoms Liver disease, liver tumors Undiagnosed abnormal vaginal bleeding Uncontrolled hypertension Women >35 years who smoke Major surgery with prolonged immobilization Diabetes mellitus with vascular involvement, jaundice with prior oral contraceptive use

Side Effect

>10% Vaginitis (13.8%),Headache (including migraine) (11.2%) 1-10% Mood changes (6.4%),Device-related events (eg, expulsion/discomfort/foreign body sensation) (6.3%),Nausea/vomiting (5.9%),Vaginal discharge (5.7%),Increased weight (4.9%),Vaginal discomfort (4%),Breast pain/discomfort,tenderness (3.8%),Dysmenorrhea (3.5%),Abdominal pain (3.2%),Acne (2.4%),Decreased libido (2%)

Pregnancy Category ID

5

Mode of Action

Estradiol is the major oestrogen in pre-menopausal women. Ethinylestradiol has similar actions as oestradiol. It is responsible for the development and maintenance of female reproductive system and secondary sexual characteristics. It also inhibits anterior pituitary by negative feedback effect and causes capillary dilation, fluid retention and protein anabolism. Etonogestrel is the active metabolite of desogestrel. It prevents pregnancy by suppressing ovulation, increasing viscosity of cervical mucous and inhibiting endometrial proliferation.

Interaction

CYP1A2 and CYP3A4 inducers such as aminoglutethimide, carbamazepine, phenobarbital, and rifampin may decrease the effects of estradiol. May enhance the effects of hydrocortisone and prednisolone when used together. Altered anticoagulant effect when used with dicoumarol. Potentially Fatal: Antibiotics (ampicillin, tetracycline, sulphonamides and chloramphenicol) can cause intermenstrual bleeding or failure of contraception. Reduced efficacy of antihypertensives or hypoglycaemic drugs. Reduced efficacy with hepatic enzyme-inducing drugs; aminoglutethimide. May inhibit ciclosporin metabolism. Changes in efficacy and safety of treatment when used in combination with protease inhibitors.